Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Nicholas C. Turner , Dennis J. Slamon , Jungsil Ro , Nicholas C. Turner , Dennis J. Slamon , Jungsil Ro , Igor Bondarenko , Seock‐Ah Im , Norikazu Masuda , Marco Colleoni , Angela DeMichele , Sherene Loi , Sunil Verma , Hiroji Iwata , Nadia Harbeck , Sibylle Loibl , Fabrice André , Kathy Puyana Theall , Xin Huang , C. Giorgetti , Cynthia Huang Bartlett , Massimo Cristofanilli
2018 New England Journal of Medicine 1,180 citations

Abstract

Among patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had sensitivity to previous endocrine therapy, treatment with palbociclib-fulvestrant resulted in longer overall survival than treatment with placebo-fulvestrant. The differences in overall survival in the entire trial group were not significant. (Funded by Pfizer; PALOMA-3 ClinicalTrials.gov number, NCT01942135 .).

Keywords

FulvestrantPalbociclibMedicineHazard ratioInternal medicineOncologyPlaceboBreast cancerMetastatic breast cancerAromatase inhibitorCancerGynecologyConfidence intervalEstrogen receptorTamoxifenPathology

Affiliated Institutions

Related Publications

Publication Info

Year
2018
Type
article
Volume
379
Issue
20
Pages
1926-1936
Citations
1180
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1180
OpenAlex

Cite This

Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro et al. (2018). Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine , 379 (20) , 1926-1936. https://doi.org/10.1056/nejmoa1810527

Identifiers

DOI
10.1056/nejmoa1810527